To evaluate the 5-Aza-‘2 and TAK981 combination treatment in B cell lymphoma, we set up a panel of ten different B cell lymphoma cell lines (Table 1), including Burkitt lymphomas which are classically MYC-driven tumors and therefore of interest for treatment with TAK981 [26, 27]. Here, MYC is linked to B-cell non-Hodgkin lymphoma.